CDC now recommends Moderna, Pfizer/BioNTech COVID-19 vaccines over Johnson & Johnson’s due to risk of fatal blood clots

Michael Walter | | Cardiovascular Business | Vascular & Endovascular
Covid Vaccine

The CDC has updated its COVID-19 vaccine recommendations for adults, announcing that vaccines developed by Moderna or Pfizer/BioNTech are preferred over the one developed by Johnson & Johnson.

One of the primary reasons for this change is the fact that Johnson & Johnson’s vaccine is associated with an elevated risk of thrombosis with thrombocytopenia syndrome (TTS), a blood-clotting issue that can potentially be fatal.

“Today’s updated recommendation emphasizes CDC’s commitment to provide real-time scientific information to the American public,” CDC Director Rochelle Walensky, MD, said in a prepared statement. “I continue to encourage all Americans to get vaccinated and boosted.”

Johnson & Johnson issued its own statement after the CDC’s announcement.

“The safety and well-being of those who use the Johnson & Johnson vaccine continues to be our No. 1 priority,” said Mathai Mammen MD, PhD, the company’s global head of Janssen research and development. “We appreciate today’s discussion and look forward to working with the CDC on next steps. In addition, we strongly support education and generating awareness of rare events, such as TTS and how to effectively manage it.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."